comparemela.com

Latest Breaking News On - Meibomian gland dysfunction - Page 9 : comparemela.com

Alcon Inc Investors: Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presence at ASCRS 2021

Alcon Inc Investors: Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presence at ASCRS 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Lumenis Receives FDA Approval for its IPL Device to Manage Dry Eye Disease and Launches OptiLight™

Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLight™ USA - English Share this article Share this article YOKNE AM ILLIT, Israel, April 29, 2021 /PRNewswire/  Lumenis Ltd., the world s largest energy-based medical device company for ophthalmic, aesthetic and surgical applications and the inventor of intense pulsed light (IPL) technology, today announced that the FDA has granted De Novo authorization for Lumenis newest IPL device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). Dry eye disease is a common disorder that causes dry, gritty, burning, tired eyes and fluctuating vision. About 16 million Americans have been diagnosed,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.